APO Research
Talk to an analyst

APO RESEARCH · REPORT

Prostate Cancer Diagnostics

The prostate is a walnut-sized gland located behind the base of a man’s penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

The prostate is a walnut-sized gland located behind the base of a man’s penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.

Prostate Cancer Diagnostics refers to using PSA, rectal exam, biopsy and others to diagnostic whether patients with breast cancer.

Selected research

Market Outlook & Growth Opportunities

Global Prostate Cancer Diagnostics Market Outlook and Growth Opportunities 2026

25 December 2025190 pages

Choose your research edition.

Industry ResearchProstate Cancer Diagnostics Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Prostate Cancer Diagnostics Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Prostate Cancer Diagnostics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Prostate Cancer Diagnostics Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Prostate Cancer Diagnostics Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The prostate is a walnut-sized gland located behind the base of a man’s penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.

Prostate Cancer Diagnostics refers to using PSA, rectal exam, biopsy and others to diagnostic whether patients with breast cancer.

Market competition is intense. Genomic Health, Abbott, OPKO, Siemens Healthcare, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers, have been formed in the monopoly position in the industry. Those key players got about 4% market shares. North America region is the largest region of Prostate Cancer Diagnostics, with a revenue market share nearly 49%. Europe is the second region of Prostate Cancer Diagnostics, enjoying revenue market share nearly 28%.

Read the full market overview

This report provides an overview of the global Prostate Cancer Diagnostics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Prostate Cancer Diagnostics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Prostate Cancer Diagnostics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Prostate Cancer Diagnostics market.

Prostate Cancer Diagnostics Segment by Company

OPKO

Genomic Health

Abbott

Beckman Coulter

Siemens Healthcare

bioMeriux

Roche

MDx Health

DiaSorin

Myriad Genetics

Ambry Genetics

Prostate Cancer Diagnostics Segment by Type

Tumor Biomarker Tests

Imaging

Biopsy

Other

Prostate Cancer Diagnostics Segment by Application

Age Below 55

Age 55-75

Age Above 75

Prostate Cancer Diagnostics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Prostate Cancer Diagnostics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Prostate Cancer Diagnostics key companies, revenue, market share, and recent developments.

3. To split the Prostate Cancer Diagnostics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Prostate Cancer Diagnostics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Prostate Cancer Diagnostics significant trends, drivers, influence factors in global and regions.

6. To analyze Prostate Cancer Diagnostics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Prostate Cancer Diagnostics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Prostate Cancer Diagnostics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Prostate Cancer Diagnostics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Prostate Cancer Diagnostics industry.

Chapter 3: Detailed analysis of Prostate Cancer Diagnostics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Prostate Cancer Diagnostics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Prostate Cancer Diagnostics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Prostate Cancer Diagnostics Industry Trends Table 2. Prostate Cancer Diagnostics Industry Drivers Table 3. Prostate Cancer Diagnostics Industry Opportunities and Challenges Table 4. Prostate Cancer Diagnostics Industry Restraints Table 5. Global Prostate Cancer Diagnostics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Prostate Cancer Diagnostics Revenue Share by Company (2021-2026) Table 7. Global Prostate Cancer Diagnostics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Prostate Cancer Diagnostics Key Company Manufacturing Base & Headquarters Table 9. Global Prostate Cancer Diagnostics Company, Product Type & Application Table 10. Global Prostate Cancer Diagnostics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Prostate Cancer Diagnostics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Tumor Biomarker Tests Table 15. Significant Companies of Imaging Table 16. Significant Companies of Biopsy Table 17. Significant Companies of Other Table 18. Global Prostate Cancer Diagnostics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Prostate Cancer Diagnostics Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Prostate Cancer Diagnostics Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Prostate Cancer Diagnostics Sales Value Share by Type (2021-2026) Table 22. Global Prostate Cancer Diagnostics Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Age Below 55 Table 24. Significant Companies of Age 55-75 Table 25. Significant Companies of Age Above 75 Table 26. Global Prostate Cancer Diagnostics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Prostate Cancer Diagnostics Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Prostate Cancer Diagnostics Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Prostate Cancer Diagnostics Sales Value Share by Application (2021-2026) Table 30. Global Prostate Cancer Diagnostics Sales Value Share by Application (2027-2032) Table 31. Global Prostate Cancer Diagnostics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Prostate Cancer Diagnostics Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Prostate Cancer Diagnostics Sales Value Share by Region (2021-2026) Table 34. Global Prostate Cancer Diagnostics Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Prostate Cancer Diagnostics Sales Value Share by Region (2027-2032) Table 36. Global Prostate Cancer Diagnostics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Prostate Cancer Diagnostics Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Prostate Cancer Diagnostics Sales Value Market Share by Country (2021-2026) Table 39. Global Prostate Cancer Diagnostics Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Prostate Cancer Diagnostics Sales Value Market Share by Country (2027-2032) Table 41. OPKO Company Information Table 42. OPKO Business Overview Table 43. OPKO Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. OPKO Prostate Cancer Diagnostics Product Portfolio Table 45. OPKO Recent Development Table 46. Genomic Health Company Information Table 47. Genomic Health Business Overview Table 48. Genomic Health Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Genomic Health Prostate Cancer Diagnostics Product Portfolio Table 50. Genomic Health Recent Development Table 51. Abbott Company Information Table 52. Abbott Business Overview Table 53. Abbott Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Abbott Prostate Cancer Diagnostics Product Portfolio Table 55. Abbott Recent Development Table 56. Beckman Coulter Company Information Table 57. Beckman Coulter Business Overview Table 58. Beckman Coulter Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Beckman Coulter Prostate Cancer Diagnostics Product Portfolio Table 60. Beckman Coulter Recent Development Table 61. Siemens Healthcare Company Information Table 62. Siemens Healthcare Business Overview Table 63. Siemens Healthcare Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Siemens Healthcare Prostate Cancer Diagnostics Product Portfolio Table 65. Siemens Healthcare Recent Development Table 66. bioMeriux Company Information Table 67. bioMeriux Business Overview Table 68. bioMeriux Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. bioMeriux Prostate Cancer Diagnostics Product Portfolio Table 70. bioMeriux Recent Development Table 71. Roche Company Information Table 72. Roche Business Overview Table 73. Roche Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Roche Prostate Cancer Diagnostics Product Portfolio Table 75. Roche Recent Development Table 76. MDx Health Company Information Table 77. MDx Health Business Overview Table 78. MDx Health Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. MDx Health Prostate Cancer Diagnostics Product Portfolio Table 80. MDx Health Recent Development Table 81. DiaSorin Company Information Table 82. DiaSorin Business Overview Table 83. DiaSorin Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. DiaSorin Prostate Cancer Diagnostics Product Portfolio Table 85. DiaSorin Recent Development Table 86. Myriad Genetics Company Information Table 87. Myriad Genetics Business Overview Table 88. Myriad Genetics Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Myriad Genetics Prostate Cancer Diagnostics Product Portfolio Table 90. Myriad Genetics Recent Development Table 91. Ambry Genetics Company Information Table 92. Ambry Genetics Business Overview Table 93. Ambry Genetics Prostate Cancer Diagnostics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 94. Ambry Genetics Prostate Cancer Diagnostics Product Portfolio Table 95. Ambry Genetics Recent Development Table 96. Research Programs/Design for This Report Table 97. Authors List of This Report Table 98. Secondary Sources Table 99. Primary Sources List of Figures Figure 1. Prostate Cancer Diagnostics Product Image Figure 2. Global Prostate Cancer Diagnostics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Prostate Cancer Diagnostics Market Size (2021-2032) & (US$ Million) Figure 4. Global Prostate Cancer Diagnostics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Tumor Biomarker Tests Image Figure 8. Imaging Image Figure 9. Biopsy Image Figure 10. Other Image Figure 11. Global Prostate Cancer Diagnostics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Prostate Cancer Diagnostics Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Prostate Cancer Diagnostics Sales Value Share by Type (2021-2032) Figure 14. Age Below 55 Image Figure 15. Age 55-75 Image Figure 16. Age Above 75 Image Figure 17. Global Prostate Cancer Diagnostics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Prostate Cancer Diagnostics Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Prostate Cancer Diagnostics Sales Value Share by Application (2021-2032) Figure 20. Global Prostate Cancer Diagnostics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Prostate Cancer Diagnostics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Prostate Cancer Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 23. North America Prostate Cancer Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Prostate Cancer Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Prostate Cancer Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Prostate Cancer Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Prostate Cancer Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Prostate Cancer Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 29. South America Prostate Cancer Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Prostate Cancer Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Prostate Cancer Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Tumor Biomarker Tests
  • Imaging
  • Biopsy
  • Other
Applications
  • Age Below 55
  • Age 55-75
  • Age Above 75
Companies covered
  • OPKO
  • Genomic Health
  • Abbott
  • Beckman Coulter
  • Siemens Healthcare
  • bioMeriux
  • Roche
  • MDx Health
  • DiaSorin
  • Myriad Genetics
  • Ambry Genetics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Prostate Cancer Diagnostics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Prostate Cancer Diagnostics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Prostate Cancer Diagnostics Market Dynamics
  1. 2.1 Prostate Cancer Diagnostics Industry Trends
  2. 2.2 Prostate Cancer Diagnostics Industry Drivers
  3. 2.3 Prostate Cancer Diagnostics Industry Opportunities and Challenges
  4. 2.4 Prostate Cancer Diagnostics Industry Restraints
3 Prostate Cancer Diagnostics Market by Company
  1. 3.1 Global Prostate Cancer Diagnostics Company Revenue Ranking in 2025
  2. 3.2 Global Prostate Cancer Diagnostics Revenue by Company (2021-2026)
  3. 3.3 Global Prostate Cancer Diagnostics Company Ranking (2024-2026)
  4. 3.4 Global Prostate Cancer Diagnostics Company Manufacturing Base and Headquarters
  5. 3.5 Global Prostate Cancer Diagnostics Company Product Type and Application
  6. 3.6 Global Prostate Cancer Diagnostics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Prostate Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Prostate Cancer Diagnostics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Prostate Cancer Diagnostics Market by Type
  1. 4.1 Prostate Cancer Diagnostics Type Introduction
  2. 4.1.1 Tumor Biomarker Tests
  3. 4.1.2 Imaging
  4. 4.1.3 Biopsy
  5. 4.1.4 Other
  6. 4.2 Global Prostate Cancer Diagnostics Sales Value by Type
  7. 4.2.1 Global Prostate Cancer Diagnostics Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Prostate Cancer Diagnostics Sales Value by Type (2021-2032)
  9. 4.2.3 Global Prostate Cancer Diagnostics Sales Value Share by Type (2021-2032)
5 Prostate Cancer Diagnostics Market by Application
  1. 5.1 Prostate Cancer Diagnostics Application Introduction
  2. 5.1.1 Age Below 55
  3. 5.1.2 Age 55-75
  4. 5.1.3 Age Above 75
  5. 5.2 Global Prostate Cancer Diagnostics Sales Value by Application
  6. 5.2.1 Global Prostate Cancer Diagnostics Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Prostate Cancer Diagnostics Sales Value by Application (2021-2032)
  8. 5.2.3 Global Prostate Cancer Diagnostics Sales Value Share by Application (2021-2032)
6 Prostate Cancer Diagnostics Regional Value Analysis
  1. 6.1 Global Prostate Cancer Diagnostics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Prostate Cancer Diagnostics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Prostate Cancer Diagnostics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Prostate Cancer Diagnostics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Prostate Cancer Diagnostics Sales Value (2021-2032)
  7. 6.3.2 North America Prostate Cancer Diagnostics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Prostate Cancer Diagnostics Sales Value (2021-2032)
  10. 6.4.2 Europe Prostate Cancer Diagnostics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Prostate Cancer Diagnostics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Prostate Cancer Diagnostics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Prostate Cancer Diagnostics Sales Value (2021-2032)
  16. 6.6.2 South America Prostate Cancer Diagnostics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Prostate Cancer Diagnostics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Prostate Cancer Diagnostics Sales Value Share by Country, 2025 VS 2032
7 Prostate Cancer Diagnostics Country-level Value Analysis
  1. 7.1 Global Prostate Cancer Diagnostics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Prostate Cancer Diagnostics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Prostate Cancer Diagnostics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Prostate Cancer Diagnostics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Prostate Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Prostate Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Prostate Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 OPKO
  2. 8.1.1 OPKO Company Information
  3. 8.1.2 OPKO Business Overview
  4. 8.1.3 OPKO Prostate Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 OPKO Prostate Cancer Diagnostics Product Portfolio
  6. 8.1.5 OPKO Recent Developments
  7. 8.2 Genomic Health
  8. 8.2.1 Genomic Health Company Information
  9. 8.2.2 Genomic Health Business Overview
  10. 8.2.3 Genomic Health Prostate Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Genomic Health Prostate Cancer Diagnostics Product Portfolio
  12. 8.2.5 Genomic Health Recent Developments
  13. 8.3 Abbott
  14. 8.3.1 Abbott Company Information
  15. 8.3.2 Abbott Business Overview
  16. 8.3.3 Abbott Prostate Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Abbott Prostate Cancer Diagnostics Product Portfolio
  18. 8.3.5 Abbott Recent Developments
  19. 8.4 Beckman Coulter
  20. 8.4.1 Beckman Coulter Company Information
  21. 8.4.2 Beckman Coulter Business Overview
  22. 8.4.3 Beckman Coulter Prostate Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Beckman Coulter Prostate Cancer Diagnostics Product Portfolio
  24. 8.4.5 Beckman Coulter Recent Developments
  25. 8.5 Siemens Healthcare
  26. 8.5.1 Siemens Healthcare Company Information
  27. 8.5.2 Siemens Healthcare Business Overview
  28. 8.5.3 Siemens Healthcare Prostate Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Siemens Healthcare Prostate Cancer Diagnostics Product Portfolio
  30. 8.5.5 Siemens Healthcare Recent Developments
  31. 8.6 bioMeriux
  32. 8.6.1 bioMeriux Company Information
  33. 8.6.2 bioMeriux Business Overview
  34. 8.6.3 bioMeriux Prostate Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 bioMeriux Prostate Cancer Diagnostics Product Portfolio
  36. 8.6.5 bioMeriux Recent Developments
  37. 8.7 Roche
  38. 8.7.1 Roche Company Information
  39. 8.7.2 Roche Business Overview
  40. 8.7.3 Roche Prostate Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Roche Prostate Cancer Diagnostics Product Portfolio
  42. 8.7.5 Roche Recent Developments
  43. 8.8 MDx Health
  44. 8.8.1 MDx Health Company Information
  45. 8.8.2 MDx Health Business Overview
  46. 8.8.3 MDx Health Prostate Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 MDx Health Prostate Cancer Diagnostics Product Portfolio
  48. 8.8.5 MDx Health Recent Developments
  49. 8.9 DiaSorin
  50. 8.9.1 DiaSorin Company Information
  51. 8.9.2 DiaSorin Business Overview
  52. 8.9.3 DiaSorin Prostate Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  53. 8.9.4 DiaSorin Prostate Cancer Diagnostics Product Portfolio
  54. 8.9.5 DiaSorin Recent Developments
  55. 8.10 Myriad Genetics
  56. 8.10.1 Myriad Genetics Company Information
  57. 8.10.2 Myriad Genetics Business Overview
  58. 8.10.3 Myriad Genetics Prostate Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Myriad Genetics Prostate Cancer Diagnostics Product Portfolio
  60. 8.10.5 Myriad Genetics Recent Developments
  61. 8.11 Ambry Genetics
  62. 8.11.1 Ambry Genetics Company Information
  63. 8.11.2 Ambry Genetics Business Overview
  64. 8.11.3 Ambry Genetics Prostate Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Ambry Genetics Prostate Cancer Diagnostics Product Portfolio
  66. 8.11.5 Ambry Genetics Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst